Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR Patents to Nuvisan

NEW YORK – Dublin-based ERS Genomics said on Monday that it has signed a non-exclusive agreement with Nuvisan allowing the firm access to ERS' CRISPR-Cas9 patent portfolio.

Nuvisan, based in Waltrop, Germany, said it will use ERS' portfolio to help advance its clients' drug discovery and early development programs.

A spinout of Bayer, Nuvisan offers integrated programs from target discovery to the clinic, including lead discovery, medicinal chemistry, pharmacology, drug metabolism, and investigational toxicology.

"[CRISPR-Cas9] is revolutionizing drug development, and we are very pleased to now be able add this capability to our service portfolio," Hans Lindner, managing director of Nuvisan, said in a statement.

Financial details of the agreement were not disclosed.

"We are pleased to provide Nuvisan … access to this Nobel Prize winning technology, further expanding the reach of the important gene editing tool and enhancing Nuvisan's portfolio of service offering to organizations in the field of drug development," Erich Rhodes, CEO of ERS Genomics, said in a statement.

ERS has signed multiple licensing deals for its CRISPR-Cas9 patent portfolio, including its most recent agreement with Japan-based Setsuro Tech last month.    

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Targets Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.